ARTICLE | Company News
PrognosDx, University of California deal
June 22, 2009 7:00 AM UTC
PrognosDx received exclusive, worldwide rights to the university's IP covering histone modification technology. PrognosDx is developing laboratory products for cancer and other diseases based on histo...